Key result
Fluvastatin significantly reduced brachial-ankle pulse wave velocity to 1,653 cm/s compared to 2,005 cm/s with bezafibrate over 5 years in patients with coronary artery disease and hyperlipidemia.
Why the study?
Does fluvastatin improve arterial stiffness in patients with coronary artery disease and hyperlipidemia?
Population
93 patients with coronary artery disease (CAD) and hyperlipidemia
Comparison
Fluvastatin vs Bezafibrate
Design
RCT, randomly assigned
Follow-up
5 years
Authors
Loading...
Supports preferring fluvastatin over bezafibrate for arterial stiffness in CAD; extends evidence for long-term vascular benefits.
RCT (n=93)
Single-blind
Randomized
No
Does fluvastatin improve arterial stiffness in patients with coronary artery disease and hyperlipidemia?
Absolute Event Rate: 1653% vs 2005%
p-value: p=<0.05
Fluvastatin provides long-term improvement in arterial stiffness in patients with CAD and hyperlipidemia, an effect that appears linked to its anti-inflammatory properties rather than lipid lowering alone.
Hongo et al. (2008) conducted an RCT in Coronary artery disease and hyperlipidemia (n=93). Fluvastatin vs. Bezafibrate (200-400 mg/day) was evaluated on Brachial-ankle pulse wave velocity (baPWV) at 5 years (p=<0.05). Fluvastatin significantly reduced brachial-ankle pulse wave velocity to 1,653 cm/s compared to 2,005 cm/s with bezafibrate over 5 years in patients with coronary artery disease and hyperlipidemia.